Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

AMARIN CORP PLC\UK Research and Development Expense

AMARIN CORP PLC\UK (AMRN) reported Research and Development Expense of $4.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-29

  • AMARIN CORP PLC\UK research and development expense for the quarter ending 2026-06-30 was $4.77M, a 2.89% decline year-over-year.
  • AMARIN CORP PLC\UK research and development expense for the quarter ending 2026-03-31 was $4.67M, a 12.18% decline year-over-year.
  • AMARIN CORP PLC\UK research and development expense for the quarter ending 2025-12-31 was $5.37M, a 10.26% decline year-over-year.
  • AMARIN CORP PLC\UK research and development expense for the quarter ending 2025-09-30 was $4.21M, a 7.31% decline year-over-year.
  • AMARIN CORP PLC\UK research and development expense for fiscal 2025 was $19.81M, a 5.09% decline from fiscal 2024.
  • AMARIN CORP PLC\UK research and development expense for fiscal 2024 was $20.87M, a 6.08% decline from fiscal 2023.
  • AMARIN CORP PLC\UK research and development expense for fiscal 2023 was $22.22M, a 26.94% decline from fiscal 2022.
  • AMARIN CORP PLC\UK research and development expense for fiscal 2022 was $30.41M, a 3.77% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$4.77M
10-Q · filed 2026-07-29
$9.44M
10-Q · filed 2026-07-29
$14.81M
derived: sum of 3 quarters · filed 2026-07-29
$19.02M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$4.67M
10-Q · filed 2026-04-29
$10.04M
derived: sum of 2 quarters · filed 2026-04-29
$14.24M
derived: sum of 3 quarters · filed 2026-04-29
$19.16M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$5.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$9.58M
derived: sum of 2 quarters · filed 2026-03-02
$14.49M
derived: sum of 3 quarters · filed 2026-07-29
$19.81M
10-K · filed 2026-03-02
2025-09-30$4.21M
10-Q · filed 2025-10-29
$9.12M
derived: sum of 2 quarters · filed 2026-07-29
$14.44M
10-Q · filed 2025-10-29
$20.42M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$4.92M
10-Q · filed 2026-07-29
$10.23M
10-Q · filed 2026-07-29
$16.21M
derived: sum of 3 quarters · filed 2026-07-29
$20.75M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$5.31M
10-Q · filed 2026-04-29
$11.30M
derived: sum of 2 quarters · filed 2026-04-29
$15.84M
derived: sum of 3 quarters · filed 2026-04-29
$20.58M
derived: sum of 4 quarters · filed 2026-04-29
2024-12-31$5.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$10.53M
derived: sum of 2 quarters · filed 2026-03-02
$15.27M
derived: sum of 3 quarters · filed 2026-03-02
$20.87M
10-K · filed 2026-03-02
2024-09-30$4.54M
10-Q · filed 2025-10-29
$9.29M
derived: sum of 2 quarters · filed 2025-10-29
$14.88M
10-Q · filed 2025-10-29
$20.68M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30$4.75M
10-Q · filed 2025-07-30
$10.34M
10-Q · filed 2025-07-30
$16.14M
derived: sum of 3 quarters · filed 2026-03-02
$21.24M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31$5.60M
10-Q · filed 2025-05-07
$11.39M
derived: sum of 2 quarters · filed 2026-03-02
$16.49M
derived: sum of 3 quarters · filed 2026-03-02
$22.14M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31$5.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$10.90M
derived: sum of 2 quarters · filed 2026-03-02
$16.54M
derived: sum of 3 quarters · filed 2026-03-02
$22.22M
10-K · filed 2026-03-02
2023-09-30$5.11M
10-Q · filed 2024-10-30
$10.75M
derived: sum of 2 quarters · filed 2024-10-30
$16.43M
10-Q · filed 2024-10-30
$21.67M
derived: sum of 4 quarters · filed 2025-03-12
2023-06-30$5.64M
10-Q · filed 2024-07-31
$11.32M
10-Q · filed 2024-07-31
$16.56M
derived: sum of 3 quarters · filed 2025-03-12
$22.33M
derived: sum of 4 quarters · filed 2025-03-12
2023-03-31$5.68M
10-Q · filed 2024-05-01
$10.92M
derived: sum of 2 quarters · filed 2025-03-12
$16.68M
derived: sum of 3 quarters · filed 2025-03-12
$26.04M
derived: sum of 4 quarters · filed 2025-03-12
2022-12-31$5.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12
$11.00M
derived: sum of 2 quarters · filed 2025-03-12
$20.36M
derived: sum of 3 quarters · filed 2025-03-12
$30.41M
10-K · filed 2025-03-12
2022-09-30$5.76M
10-Q · filed 2023-11-01
$15.12M
derived: sum of 2 quarters · filed 2023-11-01
$25.17M
10-Q · filed 2023-11-01
$30.93M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$9.36M
10-Q · filed 2023-08-02
$19.41M
10-Q · filed 2023-08-02
$25.16M
derived: sum of 3 quarters · filed 2024-02-29
$32.98M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$10.05M
10-Q · filed 2023-05-03
$15.80M
derived: sum of 2 quarters · filed 2024-02-29
$23.62M
derived: sum of 3 quarters · filed 2024-02-29
$29.98M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$5.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$13.57M
derived: sum of 2 quarters · filed 2024-02-29
$19.93M
derived: sum of 3 quarters · filed 2024-02-29
$29.31M
10-K · filed 2024-02-29
2021-09-30$7.82M
10-Q · filed 2022-10-27
$14.18M
derived: sum of 2 quarters · filed 2022-10-27
$23.55M
10-Q · filed 2022-10-27
$32.06M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$6.36M
10-Q · filed 2022-08-03
$15.73M
10-Q · filed 2022-08-03
$24.24M
derived: sum of 3 quarters · filed 2023-03-01
$34.45M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$9.38M
10-Q · filed 2022-05-04
$17.89M
derived: sum of 2 quarters · filed 2023-03-01
$28.09M
derived: sum of 3 quarters · filed 2023-03-01
$38.06M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$8.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$18.71M
derived: sum of 2 quarters · filed 2023-03-01
$28.68M
derived: sum of 3 quarters · filed 2023-03-01
$38.96M
10-K · filed 2023-03-01
2020-09-30$10.20M
10-Q · filed 2021-11-03
$20.17M
derived: sum of 2 quarters · filed 2021-11-03
$30.45M
10-Q · filed 2021-11-03
$41.55M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$9.97M
10-Q · filed 2021-08-05
$20.25M
10-Q · filed 2021-08-05
$31.34M
derived: sum of 3 quarters · filed 2022-03-01
$40.27M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$10.28M
10-Q · filed 2021-04-29
$21.38M
derived: sum of 2 quarters · filed 2022-03-01
$30.30M
derived: sum of 3 quarters · filed 2022-03-01
$37.43M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$11.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$20.02M
derived: sum of 2 quarters · filed 2022-03-01
$27.15M
derived: sum of 3 quarters · filed 2022-03-01
$34.39M
10-K · filed 2022-03-01
2019-09-30$8.92M
10-Q · filed 2020-11-05
$16.05M
derived: sum of 2 quarters · filed 2020-11-05
$23.30M
10-Q · filed 2020-11-05
$35.20M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$7.13M
10-Q · filed 2020-08-04
$14.37M
10-Q · filed 2020-08-04
$26.28M
derived: sum of 3 quarters · filed 2021-02-25
$40.35M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$7.24M
10-Q · filed 2020-04-30
$19.15M
derived: sum of 2 quarters · filed 2021-02-25
$33.22M
derived: sum of 3 quarters · filed 2021-02-25
$51.38M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$11.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$25.98M
derived: sum of 2 quarters · filed 2021-02-25
$44.14M
derived: sum of 3 quarters · filed 2021-02-25
$55.90M
10-K · filed 2021-02-25
2018-09-30$14.07M
10-Q · filed 2019-11-05
$32.23M
derived: sum of 2 quarters · filed 2019-11-05
$43.99M
10-Q · filed 2019-11-05
$55.94M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$18.16M
10-Q · filed 2019-07-31
$29.92M
10-Q · filed 2019-07-31
$41.87M
derived: sum of 3 quarters · filed 2020-02-25
$52.56M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$11.76M
10-Q · filed 2019-05-01
$23.71M
derived: sum of 2 quarters · filed 2020-02-25
$34.40M
derived: sum of 3 quarters · filed 2020-02-25
$48.10M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$11.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$22.64M
derived: sum of 2 quarters · filed 2020-02-25
$36.34M
derived: sum of 3 quarters · filed 2020-02-25
$47.16M
10-K · filed 2020-02-25
2017-09-30$10.69M
10-Q · filed 2018-11-01
$24.39M
derived: sum of 2 quarters · filed 2018-11-01
$35.21M
10-Q · filed 2018-11-01
$45.39M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$13.69M
10-Q · filed 2018-08-01
$24.52M
10-Q · filed 2018-08-01
$34.69M
derived: sum of 3 quarters · filed 2019-02-27
$48.18M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$10.82M
10-Q · filed 2018-05-02
$21.00M
derived: sum of 2 quarters · filed 2019-02-27
$34.49M
derived: sum of 3 quarters · filed 2019-02-27
$47.07M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$10.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$23.67M
derived: sum of 2 quarters · filed 2019-02-27
$36.24M
derived: sum of 3 quarters · filed 2019-02-27
$49.98M
10-K · filed 2019-02-27
2016-09-30$13.49M
10-Q · filed 2017-11-01
$26.07M
derived: sum of 2 quarters · filed 2017-11-01
$39.80M
10-Q · filed 2017-11-01
$53.15M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$12.58M
10-Q · filed 2017-08-02
$26.31M
10-Q · filed 2017-08-02
$39.66M
derived: sum of 3 quarters · filed 2018-02-27
$52.75M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$13.73M
10-Q · filed 2017-05-03
$27.08M
derived: sum of 2 quarters · filed 2018-02-27
$40.17M
derived: sum of 3 quarters · filed 2018-02-27
$52.18M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$13.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$26.44M
derived: sum of 2 quarters · filed 2018-02-27
$38.45M
derived: sum of 3 quarters · filed 2018-02-27
$51.06M
10-K · filed 2018-02-27
2015-09-30$13.09M
10-Q · filed 2016-11-03
$25.10M
derived: sum of 2 quarters · filed 2016-11-03
$37.72M
10-Q · filed 2016-11-03
$50.15M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$12.01M
10-Q · filed 2016-08-04
$24.62M
10-Q · filed 2016-08-04
$37.06M
derived: sum of 3 quarters · filed 2017-03-01
$51.52M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$12.61M
10-Q · filed 2016-05-05
$25.05M
derived: sum of 2 quarters · filed 2017-03-01
$39.51M
derived: sum of 3 quarters · filed 2017-03-01
$51.23M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$12.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$26.89M
derived: sum of 2 quarters · filed 2017-03-01
$38.62M
derived: sum of 3 quarters · filed 2017-03-01
$50.33M
10-K · filed 2017-03-01
2014-09-30$14.46M
10-Q · filed 2015-11-04
$26.18M
derived: sum of 2 quarters · filed 2015-11-04
$37.89M
10-Q · filed 2015-11-04
$54.49M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$11.73M
10-Q · filed 2015-08-06
$23.43M
10-Q · filed 2015-08-06
$40.04M
derived: sum of 3 quarters · filed 2016-02-25
$56.86M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31$11.71M
10-Q · filed 2015-05-08
$28.31M
derived: sum of 2 quarters · filed 2016-02-25
$45.13M
derived: sum of 3 quarters · filed 2016-02-25
$62.62M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31$16.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$33.42M
derived: sum of 2 quarters · filed 2016-02-25
$50.91M
derived: sum of 3 quarters · filed 2016-02-25
$72.75M
10-K · filed 2016-02-25
2013-09-30$16.82M
10-Q · filed 2014-11-06
$34.31M
derived: sum of 2 quarters · filed 2014-11-06
$56.15M
10-Q · filed 2014-11-06
$75.37M
derived: sum of 4 quarters · filed 2015-03-03
2013-06-30$17.49M
10-Q · filed 2014-08-07
$39.33M
10-Q · filed 2014-08-07
$58.55M
derived: sum of 3 quarters · filed 2015-03-03
$79.46M
derived: sum of 4 quarters · filed 2015-03-03
2013-03-31$21.84M
10-Q · filed 2014-05-09
$41.06M
derived: sum of 2 quarters · filed 2015-03-03
$61.97M
derived: sum of 3 quarters · filed 2015-03-03
$76.04M
derived: sum of 4 quarters · filed 2015-03-03
2012-12-31$19.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03
$40.13M
derived: sum of 2 quarters · filed 2015-03-03
$54.20M
derived: sum of 3 quarters · filed 2015-03-03
$58.96M
10-K · filed 2015-03-03
2012-09-30$20.91M
10-Q · filed 2013-11-07
$34.98M
derived: sum of 2 quarters · filed 2013-11-07
$39.73M
10-Q · filed 2013-11-07
$45.69M
derived: sum of 4 quarters · filed 2014-02-27
2012-06-30$14.07M
10-Q · filed 2013-08-08
$18.82M
10-Q · filed 2013-08-08
$24.77M
derived: sum of 3 quarters · filed 2014-02-27
$30.79M
derived: sum of 4 quarters · filed 2014-02-27
2012-03-31$4.76M
10-Q · filed 2013-05-09
$10.71M
derived: sum of 2 quarters · filed 2014-02-27
$16.72M
derived: sum of 3 quarters · filed 2014-02-27
$21.91M
derived: sum of 4 quarters · filed 2014-02-27
2011-12-31$5.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
$11.96M
derived: sum of 2 quarters · filed 2014-02-27
$17.15M
derived: sum of 3 quarters · filed 2014-02-27
$21.60M
10-K · filed 2014-02-27
2011-09-30$6.01M
10-Q · filed 2012-11-08
$11.20M
derived: sum of 2 quarters · filed 2012-11-08
$15.65M
10-Q · filed 2012-11-08
$23.10M
derived: sum of 4 quarters · filed 2013-02-28
2011-06-30$5.19M
10-Q · filed 2012-08-08
$9.64M
10-Q · filed 2012-08-08
$17.09M
derived: sum of 3 quarters · filed 2013-02-28
$24.73M
derived: sum of 4 quarters · filed 2013-02-28
2011-03-31$4.45M
10-Q · filed 2012-05-08
$11.90M
derived: sum of 2 quarters · filed 2013-02-28
$19.54M
derived: sum of 3 quarters · filed 2013-02-28
$27.31M
derived: sum of 4 quarters · filed 2013-02-28
2010-12-31$7.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28
$15.09M
derived: sum of 2 quarters · filed 2013-02-28
$22.86M
derived: sum of 3 quarters · filed 2013-02-28
$28.01M
10-K · filed 2013-02-28
2010-09-30$7.64M
10-Q · filed 2011-11-08
$15.41M
derived: sum of 2 quarters · filed 2011-11-08
$20.57M
10-Q · filed 2011-11-08
2010-06-30$7.77M
10-Q · filed 2011-08-09
$12.92M
10-Q · filed 2011-08-09
2009-12-31$20.89M
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B